Results 151 to 160 of about 9,514 (200)
Some of the next articles are maybe not open access.
Hypomethylating Agents for Urologic Cancers
Future Oncology, 2011Silencing of tumor suppressor genes by promoter-region methylation as an epigenetic mechanism of gene regulation is increasingly recognized as beneficial in cancer. Initially developed as cytotoxic high-dose therapies, azacitidine and decitabine are now being reinvestigated in lower-dose cancer treatment regimens with a different paradigm ...
, Sarvari Yellapragada, Rakesh Singal
exaly +3 more sources
Hypomethylating Agents in Lymphoma
Current Treatment Options in Oncology, 2020Epigenetic mutations are frequent and pathogenic in select subtypes of lymphoma, and agents modulating DNA and histone methylation-such as inhibitors of DNMT and EZH2, respectively-have demonstrated promise in treating these diseases. In particular, lymphomas derived from the germinal center-GC-DLBCL, FL, and AITL-are all characterized by epigenetic ...
Jacob C, Cogan +2 more
openaire +2 more sources
Hypomethylating agents and chemotherapy in MDS
Best Practice & Research Clinical Haematology, 2013Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline-AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype ...
Adès, Lionel, SANTINI, VALERIA
openaire +3 more sources
Hypomethylating Agents as a Therapy for AML
Current Hematologic Malignancy Reports, 2017Acute myeloid leukemia (AML) is predominantly a disease of older adults associated with poor long-term outcomes with available therapies. Used as single agents, hypomethylating agents (HMAs) induce only 15 to 25% complete remissions, but current data suggest that median OS observed after HMAs is comparable to that observed after more intensive ...
Claude, Gardin, Hervé, Dombret
openaire +2 more sources
Curcumin is a potent DNA hypomethylation agent
Bioorganic & Medicinal Chemistry Letters, 2009Molecular docking of the interaction of curcumin and DNMT1 suggested that curcumin covalently blocks the catalytic thiolate of C1226 of DNMT1 to exert its inhibitory effect. This was validated by showing that curcumin inhibits the activity of M. SssI with an IC(50) of 30 nM, but no inhibitory activity of hexahydrocurcumin up to 100 microM. In addition,
Zhongfa, Liu +11 more
openaire +2 more sources
Future Directions for the Use of Hypomethylating Agents
Seminars in Hematology, 2005Epigenetics refers to heritable changes in DNA and chromatin that impact gene expression without a change in DNA sequence. Two major steps involved in epigenetic regulation of gene expression include methylation of the promoter region of the gene and deacetylation of specific lysine residues on promoter-associated histones leading to changes in ...
Guillermo, Garcia-Manero, Steven D, Gore
openaire +2 more sources
Optimizing hypomethylating agents in myelodysplastic syndromes
Current Opinion in Hematology, 2012Hypomethylating agents (HMAs) improve the outcome of higher-risk myelodysplastic syndromes (MDS) and provide multilineage response in lower-risk patients but their results must be optimized, especially as the poor outcome of patients after HMA failure is now established.Current efforts include evaluation of novel outpatient administration schedules and
Raphael, Itzykson, Pierre, Fenaux
openaire +2 more sources
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
Current Hematologic Malignancy Reports, 2023To discuss novel targeted therapies under investigation for treatment of myelodysplastic neoplasms (MDS).Over the last few years, results of phase 3 trials assessing novel therapies for high-risk MDS have been largely disappointing. Pevonedistat (NEDD-8 inhibitor) and APR-246 (TP53 reactivator) both did not meet trial endpoints.
Prateek Pophali +2 more
openaire +2 more sources
Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors
Best Practice & Research Clinical Haematology, 2023Myeloid malignancies such as myelodysplastic syndrome (MDS) & acute myeloid leukemia (AML) are clonal diseases that emerge and progress due to the expansion of disease-initiating aberrant hematopoietic stem cells, that are not eliminated by conventional cytotoxic therapies.
Sudhamsh Reddy, Desai +2 more
openaire +2 more sources
Making the most of hypomethylating agents in myelodysplastic syndromes
Current Opinion in Hematology, 2017Purpose of review Hypomethylating agents (HMA) are the preferred therapy for patients with higher risk myelodysplastic syndromes (MDS) and an alternative therapeutic strategy for older patients with acute myeloid leukemia. These agents have improved both survival and quality of life, but results overall remain poor. The purpose
Geetika, Bhatt, William, Blum
openaire +2 more sources